Inogen, Inc. has appointed Andy Reding to the newly created role of Chief Operating Officer, effective July 6, 2026, to strengthen its leadership structure and support global commercial and operational execution. The medical technology company, listed on Nasdaq under the ticker INGN, aims to streamline operations as it diversifies through new product launches and geographic expansion. Reding will be responsible for driving revenue and operational performance, aligning cross-functional priorities, and ensuring the company's strategy translates into efficient outcomes.

Executive Background

Andy Reding joins Inogen with more than 30 years of leadership experience across medical technology, commercial operations, product development, and healthcare reimbursement. Most recently, he served as Chief Commercial Officer of Viant Medical for over six years, leading teams across 25 facilities that support complex medical-device design and manufacturing programs. His tenure at Viant was marked by exceptional growth and support for hundreds of medical device companies globally.

Prior to his role at Viant Medical, Reding was Vice President and General Manager of Hillrom Respiratory Health. In this capacity, he led sales, marketing, customer service, research and development, reimbursement, and third-party billing. His team expanded the sales force, developed new products, and navigated FDA and CMS requirements to bring innovative products to market. Reding holds a Master of Business Administration from the University of South Carolina and a bachelor’s degree from Marquette University.

Strategic Appointment

Kevin Smith, Chief Executive Officer of Inogen, stated that the new appointment is designed to enhance execution and accelerate the delivery of strategic priorities. Smith highlighted Reding’s deep experience in building high-performing teams and scaling complex medical technology businesses as critical for driving top-line growth, advancing profitability, and expanding the innovation pipeline. Reding expressed his commitment to transforming Inogen into a global respiratory care leader by leveraging the company's strong foundation and mission.

Compensation Details

In connection with his employment, Andy Reding received an inducement equity award consisting of restricted stock units (RSUs) covering an aggregate of 130,000 shares of Inogen’s common stock. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4). Subject to Reding’s continued service with the company, one-third of the RSUs will vest annually over a period of three years.